title: Therapeutic monoclonal antibody concentration monitoring: free or total?
abstract: Most therapeutic monoclonal antibodies are designed to bind a specific antigen to elicit pharmacological effects. Accurate quantification of a therapeutic monoclonal antibody in biological matrices is essential for assessing its pharmacokinetics and selecting an effective dosing regimen. Therapeutic antibodies may exist in free, partially bound and fully bound forms in the bloodstream. The choice of which form(s) to measure and how to measure them is gaining much attention with the increase in the number of soluble therapeutic targets. This article will review the bioanalytical methods used in supporting the clinical development of the US FDA-approved therapeutic monoclonal antibodies and also discuss how different factors, such as assay format, target and antibody concentrations, and sample dilutions, can have an impact on the measurement of each form of antibody. Appreciation of which form of drug is being measured and what factors may impact measurement under different conditions are important for interpretation of the pharmacokinetics of therapeutic antibodies.
authors.affiliation: Pharmacokinetics, Dynamics and Metabolism, Biotherapeutics Research and Development, Pfizer Inc. San Diego, CA 92121, USA. bing.kuang@pfizer.com
authors.forename: Bing
authors.initials: B
authors.lastname: Kuang
authors.forename: Lindsay
authors.initials: L
authors.lastname: King
authors.forename: Huifen Faye
authors.initials: HF
authors.lastname: Wang
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000032:analysis* / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use*; D000941:Antigens / Q000276:immunology; D001667:Binding, Competitive; D002462:Cell Membrane / Q000378:metabolism; D006801:Humans; D007118:Immunoassay / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D000941:Antigens